NUTM1
Overview
NUTM1 (Nuclear protein in testis midline carcinoma 1) is a chromatin-regulatory protein whose rearrangement with bromodomain-containing genes (most commonly BRD4) defines NUT carcinoma, an aggressive epithelial malignancy. BRD4-NUTM1 fusions drive oncogenesis by blocking differentiation through aberrant histone acetylation. NUT carcinoma most often arises in midline locations but can occur in the thymus and other sites.
Alterations observed in the corpus
- BRD4-NUTM1 fusion present in TY82 thymic carcinoma cell line, establishing NUT carcinoma as a molecular subtype of thymic carcinoma PMID:24974848
- NUTM1–BRD4 fusion identified in 1 ATC case by targeted RNA-seq; NUT carcinoma-defining fusion found in a single anaplastic thyroid carcinoma case in this 341-gene panel study PMID:26878173
Cancer types (linked)
- Thymic carcinoma (THYM): BRD4-NUTM1 fusion identified in TY82 cell line; NUT carcinoma represents a molecularly distinct aggressive subtype within thymic epithelial tumors PMID:24974848
Co-occurrence and mutual exclusivity
- No co-occurrence or mutual exclusivity data in the current corpus.
Therapeutic relevance
- BRD4-NUTM1 fusion tumors are sensitive to BET bromodomain inhibitors (e.g., JQ1) in preclinical models; no clinical data specific to thymic NUT carcinoma reported in this corpus PMID:24974848
Open questions
- Clinical frequency of BRD4-NUTM1 fusions among thymic carcinomas beyond the TY82 cell line context remains uncharacterized in population cohorts PMID:24974848
Sources
This page was processed by entity-page-writer on 2026-05-11. - PMID:26878173
This page was processed by wiki-cli on 2026-05-14.